CytoMed Therapeutics director reports share disposals

CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong reported two non-derivative transactions in ordinary shares of CytoMed Therapeutics Limited.

Accepted by SEC EDGAR 07/24/2026 - 12:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong reported two non-derivative transactions in ordinary shares of CytoMed Therapeutics Limited. On July 20, 2026 and July 14, 2026, he recorded dispositions of 100,000 shares each at $1.50 per share. Both transactions are classified as direct ownership, and no post-transaction share balance is reported in this disclosure.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 2 txns

Insider Choo Chee Kong

Role Director, 10% Owner

Bought 200,000 shs ($300K)

Type	Security	Shares	Price	Value
Purchase	ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED	100,000	$1.50	$150K
Purchase	ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED	100,000	$1.50	$150K

Holdings After Transaction: ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED — 630,324 shares (Direct)

Key Figures

Disposition on 2026-07-20: 100,000 shares Disposition on 2026-07-14: 100,000 shares Per-share price: $1.50 per share +1 more

4 metrics

Disposition on 2026-07-20 100,000 shares Non-derivative ordinary shares classified as a disposition at $1.50 per share

Disposition on 2026-07-14 100,000 shares Non-derivative ordinary shares classified as a disposition at $1.50 per share

Per-share price $1.50 per share Reported price for each of the two 100,000-share non-derivative transactions

Reported disposition count 2 transactions Total number of non-derivative ordinary share dispositions in this disclosure

Key Terms

non-derivative, ordinary shares, direct ownership, disposition

4 terms

non-derivative financial

"Each transaction is categorized as a non-derivative ordinary share transaction."

ordinary shares financial

"Security title is listed as ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

direct ownership financial

"The ownership_type field identifies these positions as direct ownership."

disposition financial

"The transaction_direction field classifies both entries as a disposition."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GDTC director Choo Chee Kong report?

Choo Chee Kong reported two non-derivative dispositions of CytoMed Therapeutics ordinary shares. Each transaction involved 100,000 shares at $1.50 per share, recorded on July 14, 2026 and July 20, 2026, under direct ownership.

How many CytoMed Therapeutics (GDTC) shares were involved in the recent insider activity?

The insider activity covered a total of 200,000 ordinary shares. It consisted of two separate transactions, each for 100,000 shares, both categorized as non-derivative dispositions under direct ownership at a reported price of $1.50 per share.

At what price were the GDTC shares traded in the reported insider transactions?

Both reported transactions used a price of $1.50 per share. On July 14, 2026 and July 20, 2026, Choo Chee Kong disposed of 100,000 ordinary shares on each date at this same per-share price, according to the disclosure data.

Were the CytoMed Therapeutics (GDTC) insider transactions classified as derivative or non-derivative?

The transactions were classified as non-derivative ordinary share transactions. Each entry identifies “ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED” as the security title, with direct ownership and no associated derivative securities reported in this disclosure.

Does the CytoMed Therapeutics (GDTC) insider disclosure indicate a Rule 10b5-1 trading plan?

The Rule 10b5-1 affirmation checkbox is not marked as true in this disclosure. The data do not attribute these two non-derivative ordinary share dispositions to a pre-arranged Rule 10b5-1 trading plan within the reported information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Choo Chee Kong

(Last) (First) (Middle)

#08-22 ONE COMMONWEALTH, 1

COMMONWEALTH LANE

(Street)

SINGAPORE U0 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED	07/14/2026		P		100,000	D	$1.5	530,324	D
ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED	07/20/2026		P		100,000	D	$1.5	630,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ CHOO CHEE KONG	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)